文献速递泌尿系结石

英国肾结石疾病经济负担评估:平均随访19年的回顾性队列研究

Evaluation of the economic burden of kidney stone disease in the UK: a retrospective cohort study with a mean follow-up of 19 years.
PubMed 文献 · BJU Int · 2020-01-24

该研究基于1990至2007年间转诊至代谢结石门诊的781例肾结石患者电子记录,按2018年NHS收费标准估算费用并外推至英格兰总人口。肾结石疾病经济负担与前列腺癌和膀胱癌合计费用相当。

要点

  • 每次发作平均总费用为1277至2887英镑(2018年NHS收费标准)

核心结论

  • 肾结石疾病是花费高昂的疾病,其经济负担与英国前列腺癌和膀胱癌的合计费用相当。

研究设计与样本

  • 回顾性队列研究,纳入1990至2007年间转诊至三级转诊中心代谢结石门诊的781例肾结石患者,平均随访19年,按2018年NHS收费标准估算费用并外推至英格兰总人口。

主要发现

  • 每次发作平均总费用在1277英镑(SD 1724)至2887英镑(SD 2492)之间。

关键数值与推荐

  • 排除无记录及随访不足5年的患者。
  • 费用按2018年NHS收费标准计算,以较低和较高估计值呈现每次发作、队列内总费用及队列和英格兰总人口的初始、5年、10年和15年费用。
  • 采用线性回归分析每次发作费用和总费用的显著预测因素。

临床怎么用

  • 肾结石疾病的经济负担与前列腺癌和膀胱癌合计费用相当,提示临床和卫生政策制定中应重视其长期费用管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the cost of kidney stone disease (KSD) in England. PATIENTS AND METHODS: We conducted a retrospective cohort study of patients with KSD, referred to a metabolic stone clinic between 1990 and 2007 using electronic records of patients with KSD in a tertiary referral centre, to determine cost using UK National Health Service (NHS) tariff, with subsequent extrapolation to the entire England population. Those with no documentation and <5 years follow-up were excluded. The outcome measure was calculation of cost (as per 2018 NHS tariff) presented as lower and higher estimates for: per episode; total within the cohort; and estimation of initial, 5-,10- and 15-year costs for the cohort and total population in England. Linear regression was used to examine for significant predictors of per episode and total cost. RESULTS: A total of 781 patients were included in the study after 1000 records were screened for inclusion, with a mean follow-up of 19 years. The mean (SD) overall costs per episode were between £1277 (1724) and £2887 (2492). Total initial costs for the cohort were between £950 842 and £2 336 442, rising to between £1.43 million and £3.02 million at 15 years of follow-up. Estimated cost in 2010 in England alone was between £190 million and £324 million. CONCLUSION: KSD is a costly disease, comparable to the combined cost of prostate and bladder cancer in UK.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Geraghty RM, Cook P, Walker V, et al. Evaluation of the economic burden of kidney stone disease in the UK: a retrospective cohort study with a mean follow-up of 19 years. BJU Int. 2020. PMID: 31916369. doi:10.1111/bju.14991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。